ATAI Life Sciences AG was founded in 2018 by the Apeiron Investment Group Ltd, the home office of German entrepreneur and investor Christian Angermayer. The company name is adapted from the ancient African goddess of creation Atai who was the wife of Abassi the Supreme Creator of the universe. ATAI recently raised $25 million from investors like Icelandic entrepreneur Thor Bjorgolfsson and former hedge fund manager Mike Novogratz.
According to their webpage, ATAI Life Sciences has “a special passion for psychedelics.” What makes the company unique is their quest to harness artificial intelligence (AI) and big data solutions to enhance mental health and longevity. Their goal is to develop and acquire promising therapeutic technologies that focus on longevity and mental well-being.
One of ATAI’s holdings, COMPASS Pathways, is developing a psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.